SCHEDULE 13G/A: Perceptive Advisors Discloses 7.0% Stake in Amicus Therapeutics

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has reported a collective beneficial ownership of 7.0% in Amicus Therapeutics, Inc. common stock.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 4 to Schedule 13G.
• The Reporting Persons collectively beneficially own 21,464,527 shares of Amicus Therapeutics, Inc. common stock.
• This ownership represents 7.0% of the Issuer's outstanding common stock.
• The percentage is calculated based on 307,930,984 shares of Common Stock outstanding as of April 24, 2025, as reported in Amicus Therapeutics' Quarterly Report on Form 10-Q filed on May 1, 2025.
• Perceptive Life Sciences Master Fund, Ltd. directly holds the 21,464,527 shares.
• Perceptive Advisors LLC serves as the investment manager to the Master Fund and is deemed to beneficially own the shares.
• Joseph Edelman, as the managing member of Perceptive Advisors LLC, is also deemed to beneficially own the shares.
• All Reporting Persons share both voting and dispositive power over the 21,464,527 shares.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive due to the disclosure of a significant, passive stake by a reputable life sciences investment firm, which can be interpreted as a vote of confidence in the company.

Positives

• The disclosure of a significant 7.0% stake by a specialized life sciences investment firm like Perceptive Advisors may signal confidence in Amicus Therapeutics' long-term prospects and strategy.
• The filing indicates that the shares are not held for the purpose of changing or influencing the control of the issuer, suggesting a passive investment intent.

Risks

• No specific risks related to the issuer's operations or financial health are disclosed in this beneficial ownership report, as its primary purpose is to report ownership levels.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Amicus Therapeutics, Inc.'s future performance or outlook.

Industry Context

Perceptive Advisors LLC is a prominent investment firm specializing in the life sciences sector. Their continued significant stake in Amicus Therapeutics, a biotechnology company, reflects ongoing institutional interest and investment in the pharmaceutical and rare disease treatment industry.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership exceeding 5% by an institutional investor, as required by SEC regulations. It does not provide performance metrics for comparison to industry standards.
• The ownership stake by Perceptive Advisors, a well-known life sciences fund, aligns with typical investment strategies of specialized funds focusing on specific sectors.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence investor perception and potentially stock liquidity.
• Company Management: Awareness of a large, passive institutional investor on their shareholder register.

Next Steps

• Amicus Therapeutics, Inc. will continue its regular SEC reporting, including quarterly and annual financial statements.
• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. will file further amendments to this Schedule 13G if their beneficial ownership percentage changes significantly (e.g., by more than 1%).

Key Dates

Keywords

Amicus Therapeutics, Perceptive Advisors, Joseph Edelman, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Pharmaceuticals, Institutional Investor, SEC Filing